By directly inhibiting mutant-driven oncogenic signaling, avapritinib suppresses cell proliferation, promotes apoptosis, and reduces tumor vascular support indirectly, given that PDGFRA-mutant tumors often induce pro-angiogenic microenvironments [154]. This evidence concerns the gene PDGFRA and neoplasm.